» Articles » PMID: 36936214

A Multicenter Comparative Study of the Performance of Four Rapid Immunochromatographic Tests for the Detection of Anti- Antibodies in Brazil

Abstract

Diagnosis of () infection in the chronic phase of Chagas disease (CD) is performed by serologic testing. Conventional tests are currently used with very good results but require time, laboratory infrastructure, and expertise. Rapid diagnostic tests (RDTs) are an alternative as the results are immediate and do not require specialized knowledge, making them suitable for epidemiologic studies and promising as a screening tool. Nevertheless, few studies conducted comparative evaluations of RDTs to validate the results and assess their performance. In this study, we analyzed four trades of rapid tests (OnSite Chagas Ab Combo Rapid Test-United States, SD Bioline Chagas AB-United States, WL Check Chagas-Argentina, and TR Chagas Bio-Manguinhos-Brazil) using a panel of 190 samples, including sera from 111 infected individuals, most of whom had low antibody levels. An additional 59 samples from uninfected individuals and 20 sera from individuals with other diseases, mainly visceral leishmaniasis, were included. All tests were performed by three independent laboratories in a blinded manner. Results showed differences in sensitivity from 92.8 to 100%, specificity from 78.5 to 92.4%, and accuracy from 90.5 to 95.3% among the four assays. The results presented here show that all four RDTs have high overall diagnostic ability. However, WL Check Chagas and TR Chagas Bio-Manguinhos were considered most suitable for use in screening studies due to their high sensitivity combined with good performance. Although these two RDTs have high sensitivity, a positive result should be confirmed with other tests to confirm or rule out reactivity/positivity, especially considering possible cross-reactivity with individuals with leishmaniasis or toxoplasmosis.

Citing Articles

Performance of Extracellular Vesicles From () for Serological Diagnosis of Human and Canine Visceral Leishmaniasis.

da Cruz A, Carneiro F, Taniwaki N, Namiyama G, Dos Santos D, Castellao K J Parasitol Res. 2025; 2025:8355886.

PMID: 39877665 PMC: 11774571. DOI: 10.1155/japr/8355886.


The Oxente Chagas Bahia Project: evaluating the efficacy of a rapid diagnostic test and treatments for Chagas disease.

Santos F, Pavan T, Valle C, Sampaio D, Vasconcelos L, Cristobal M Mem Inst Oswaldo Cruz. 2024; 119:e240140.

PMID: 39476029 PMC: 11520660. DOI: 10.1590/0074-02760240140.


Recombinant proteins as promising antigens applied to the immunodiagnosis of Chagas disease: a scoping review.

Resende C, Ribeiro A, Gandra I, Silva K, Lopes L, Barcelos I Front Microbiol. 2024; 15:1420226.

PMID: 39139374 PMC: 11319188. DOI: 10.3389/fmicb.2024.1420226.


Evaluation of chimeric recombinant antigens for the serodiagnosis of Trypanosoma cruzi in dogs: a promising tool for Chagas disease surveillance.

Fontes N, Habib F, Leony L, Freitas N, Silva A, Dantas-Torres F Parasit Vectors. 2024; 17(1):305.

PMID: 39010122 PMC: 11251128. DOI: 10.1186/s13071-024-06376-5.


diagnostic methods of Chagas disease in the clinical laboratory: a scoping review.

Ascanio L, Carroll S, Paniz-Mondolfi A, Ramirez J Front Microbiol. 2024; 15:1393992.

PMID: 38746745 PMC: 11091413. DOI: 10.3389/fmicb.2024.1393992.


References
1.
Sanchez-Camargo C, Albajar-Vinas P, Wilkins P, Nieto J, Leiby D, Paris L . Comparative evaluation of 11 commercialized rapid diagnostic tests for detecting Trypanosoma cruzi antibodies in serum banks in areas of endemicity and nonendemicity. J Clin Microbiol. 2014; 52(7):2506-12. PMC: 4097696. DOI: 10.1128/JCM.00144-14. View

2.
Zingales B . Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Trop. 2017; 184:38-52. DOI: 10.1016/j.actatropica.2017.09.017. View

3.
Bern C, Montgomery S . An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009; 49(5):e52-4. DOI: 10.1086/605091. View

4.
Chaves G, Abi-Saab Arrieche M, Rode J, Mechali D, Reis P, Alves R . [Estimating demand for anti-Chagas drugs: a contribution for access in Latin America]. Rev Panam Salud Publica. 2017; 41:e45. PMC: 6612731. View

5.
Santos F, Celedon P, Zanchin N, Leitolis A, Crestani S, Foti L . Performance Assessment of a Trypanosoma cruzi Chimeric Antigen in Multiplex Liquid Microarray Assays. J Clin Microbiol. 2017; 55(10):2934-2945. PMC: 5625379. DOI: 10.1128/JCM.00851-17. View